Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.65 USD
−117.86 M USD
0.00 USD
59.88 M
About Vor Biopharma Inc.
Sector
Industry
CEO
Bob Ang
Website
Headquarters
Cambridge
Founded
2015
FIGI
BBG00NBJRDT6
Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a single company solution for patients suffering from hematological malignancies. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Cambridge, MA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of VOR is 0.98 USD — it has increased by 2.91% in the past 24 hours. Watch Vor Biopharma Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Vor Biopharma Inc. stocks are traded under the ticker VOR.
VOR stock has risen by 18.00% compared to the previous week, the month change is a 9.68% rise, over the last year Vor Biopharma Inc. has showed a −56.42% decrease.
We've gathered analysts' opinions on Vor Biopharma Inc. future price: according to them, VOR price has a max estimate of 18.00 USD and a min estimate of 8.00 USD. Watch VOR chart and read a more detailed Vor Biopharma Inc. stock forecast: see what analysts think of Vor Biopharma Inc. and suggest that you do with its stocks.
VOR stock is 8.31% volatile and has beta coefficient of 1.73. Track Vor Biopharma Inc. stock price on the chart and check out the list of the most volatile stocks — is Vor Biopharma Inc. there?
Today Vor Biopharma Inc. has the market capitalization of 70.05 M, it has increased by 15.95% over the last week.
Yes, you can track Vor Biopharma Inc. financials in yearly and quarterly reports right on TradingView.
Vor Biopharma Inc. is going to release the next earnings report on Mar 20, 2025. Keep track of upcoming events with our Earnings Calendar.
VOR earnings for the last quarter are −0.40 USD per share, whereas the estimation was −0.40 USD resulting in a 0.55% surprise. The estimated earnings for the next quarter are −0.33 USD per share. See more details about Vor Biopharma Inc. earnings.
Vor Biopharma Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
VOR net income for the last quarter is −27.56 M USD, while the quarter before that showed −27.84 M USD of net income which accounts for 1.01% change. Track more Vor Biopharma Inc. financial stats to get the full picture.
No, VOR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 18, 2024, the company has 168.00 employees. See our rating of the largest employees — is Vor Biopharma Inc. on this list?
Like other stocks, VOR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Vor Biopharma Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Vor Biopharma Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Vor Biopharma Inc. stock shows the sell signal. See more of Vor Biopharma Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.